Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study
After curative resection of stage II colon cancer, adjuvant chemotherapy with 5-fluorouracil/leucovorin (FL) or capecitabine is selectively recommended. However, there is little evidence of the effect of capecitabine on oncologic outcome in geriatric patients with stage II colon cancer compared to that of FL. The aim of this study was to determine the difference in recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in patients older than 70 years of age with stage II colon cancer receiving capecitabine and FL.
Patients over 70 years of age diagnosed with primary pathologic stage II colon cancer at the Seoul National University Hospital from January 2005 to December 2015 were included. A prospectively collected database was analyzed retrospectively. Patients were separated into an FL group and a capecitabine group. The primary outcomes were RFS, CSS, and OS.
Of the 154 included patients, 96 patients received FL and 58 patients received capecitabine. There was no difference between the two groups in RFS, CSS, or OS (p = 0.763, p = 0.221, and p = 0.470, respectively) as measured by Kaplan–Meier analysis with log-rank test. Administration of capecitabine as compared to FL was not a factor affecting RFS (hazard ratio [HR] 0.503, 95% confidence interval [CI] 0.145–1.745), CSS (HR 1.519, 95% CI 0.348–6.629), or OS (HR 0.941, 95% CI 0.290–3.053) on multivariable analysis.
Capecitabine is a safe regimen in terms of oncologic outcomes compared with FL in older patients with stage II colon cancer.
KeywordsGeriatric patients Colon cancer Stage II Capecitabine 5-Fluorouracil/leucovorin
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2017R1D1A1B03036191).
Compliance with ethical standards
This study was conducted with the approval of the institutional review board (IRB) of Seoul National University Hospital. Requirement for consent was waived with permission from the IRB. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T et al (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30:3353–3360. https://doi.org/10.1200/JCO.2012.42.5645 CrossRefGoogle Scholar
- 7.Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516. https://doi.org/10.1200/JCO.2004.05.063 CrossRefGoogle Scholar
- 8.Reha J, Mukkamalla SKR, Rathore R, Somasundar PS (2018) Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: a validation study using the National Cancer Data Base. Eur J Surg Oncol 44:148–156. https://doi.org/10.1016/j.ejso.2017.11.005 CrossRefGoogle Scholar
- 9.Poeschl EM, Pollheimer MJ, Kornprat P, Lindtner RA, Schlemmer A, Rehak P et al (2010) Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer. J Clin Oncol 28:e358–e360. https://doi.org/10.1200/JCO.2009.27.3581 CrossRefGoogle Scholar
- 10.Cienfuegos JA, Martinez P, Baixauli J, Beorlegui C, Rosenstone S, Sola JJ et al (2017) Perineural invasion is a major prognostic and predictive factor of response to adjuvant chemotherapy in stage I-II colon cancer. Ann Surg Oncol 24:1077–1084. https://doi.org/10.1245/s10434-016-5561-0 CrossRefGoogle Scholar
- 12.Tan WP, Talbott VA, Leong QQ, Isenberg GA, Goldstein SD (2013) American Society of Anesthesiologists class and Charlson’s comorbidity index as predictors of postoperative colorectal anastomotic leak: a single-institution experience. J Surg Res 184:115–119. https://doi.org/10.1016/j.jss.2013.05.039 CrossRefGoogle Scholar
- 13.Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219–3226. https://doi.org/10.1200/JCO.2009.27.1825 CrossRefGoogle Scholar